These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30740243)

  • 1. Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments.
    Vandendorpe AS; de Vlam K; Lories R
    RMD Open; 2019; 5(1):e000779. PubMed ID: 30740243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.
    Raychaudhuri SP; Wilken R; Sukhov AC; Raychaudhuri SK; Maverakis E
    J Autoimmun; 2017 Jan; 76():21-37. PubMed ID: 27836567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Karki C; Palmer JB; Etzel CJ; Kavanaugh A; Ritchlin CT; Malley W; Herrera V; Tran M; Greenberg JD
    Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1692-1699. PubMed ID: 28376239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI).
    Mease PJ
    Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11():S64-85. PubMed ID: 22588772
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and efficacy of therapies for skin symptoms of psoriasis in patients with psoriatic arthritis: a systematic review.
    Boehncke WH; Alvarez Martinez D; Solomon JA; Gottlieb AB
    J Rheumatol; 2014 Nov; 41(11):2301-5. PubMed ID: 25362715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy.
    Chandran V; Maharaj AB
    Expert Rev Clin Immunol; 2016; 12(5):573-82. PubMed ID: 26807494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
    Mease PJ; Boehncke WH; Gladman DD
    J Rheumatol; 2013 Aug; 40(8):1407-9. PubMed ID: 23908533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study.
    Ballegaard C; Jørgensen TS; Skougaard M; Strand V; Mease PJ; Kristensen LE; Dreyer L; Gottlieb A; de Wit M; Christensen R; Tarp S
    Arthritis Care Res (Hoboken); 2018 Aug; 70(8):1206-1217. PubMed ID: 29073353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.
    Holland R; Tillett W; Ogdie A; Leung YY; Gladman DD; Callis Duffin K; Coates LC; Mease PJ; Eder L; Strand V; Elmamoun M; Højgaard P; Chau J; de Wit M; Goel N; Lindsay CA; FitzGerald O; Shea B; Beaton D; Orbai AM
    J Rheumatol Suppl; 2018 Jun; 94():17-25. PubMed ID: 29858348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of disease activity measures for psoriatic arthritis: what is the best approach?
    Her M; Kavanaugh A
    Expert Rev Clin Immunol; 2014 Sep; 10(9):1241-54. PubMed ID: 25088300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
    Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
    Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of biological agents in the treatment of psoriatic arthritis, literature review].
    Koó E; Brodszky V; Péntek M; Ujfalussy I; Nagy MB; Gulácsi L
    Orv Hetil; 2006 Oct; 147(41):1963-70. PubMed ID: 17120686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis.
    Healy PJ; Helliwell PS
    Arthritis Rheum; 2008 May; 59(5):686-91. PubMed ID: 18438903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Psoriatic arthritis].
    Cauza E; Dunky A
    Wien Med Wochenschr; 2006 Nov; 156(21-22):587-95. PubMed ID: 17160376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA.
    Coates LC; Kavanaugh A; Ritchlin CT;
    J Rheumatol; 2014 Nov; 41(11):2273-6. PubMed ID: 25362710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014.
    Tillett W; Eder L; Goel N; De Wit M; Gladman DD; FitzGerald O; Campbell W; Helliwell PS; Gossec L; Orbai AM; Ogdie A; Strand V; McHugh NJ; Mease PJ
    J Rheumatol; 2015 Nov; 42(11):2198-203. PubMed ID: 25934828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for psoriatic arthritis.
    Caso F; Del Puente A; Peluso R; Caso P; Girolimetto N; Del Puente A; Scarpa R; Costa L
    Expert Opin Emerg Drugs; 2016; 21(1):69-79. PubMed ID: 26807876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Features and Diagnostic Considerations in Psoriatic Arthritis.
    Gladman DD
    Rheum Dis Clin North Am; 2015 Nov; 41(4):569-79. PubMed ID: 26476219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinguishing inflammatory from noninflammatory arthritis, enthesitis, and dactylitis in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting.
    Mease PJ
    J Rheumatol; 2012 Feb; 39(2):415-7. PubMed ID: 22298269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.